IO Biotech (NASDAQ:IOBT - Get Free Report) was upgraded by equities research analysts at Wall Street Zen to a "sell" rating in a research note issued on Saturday.
Several other brokerages have also issued reports on IOBT. Piper Sandler raised IO Biotech to a "strong-buy" rating in a research report on Wednesday, March 12th. HC Wainwright reissued a "buy" rating on shares of IO Biotech in a report on Wednesday, May 14th.
Get Our Latest Analysis on IO Biotech
IO Biotech Stock Down 10.0%
IOBT stock opened at $1.35 on Friday. The company has a market cap of $88.94 million, a price-to-earnings ratio of -0.99 and a beta of 0.36. IO Biotech has a twelve month low of $0.66 and a twelve month high of $1.73. The business has a 50 day moving average price of $1.10 and a two-hundred day moving average price of $0.98.
Hedge Funds Weigh In On IO Biotech
A number of hedge funds have recently bought and sold shares of the business. Jane Street Group LLC purchased a new stake in IO Biotech during the 1st quarter valued at $26,000. XTX Topco Ltd purchased a new stake in IO Biotech during the fourth quarter valued at $26,000. Vontobel Holding Ltd. bought a new position in IO Biotech in the fourth quarter valued at about $30,000. Renaissance Technologies LLC boosted its position in IO Biotech by 22.5% in the fourth quarter. Renaissance Technologies LLC now owns 118,800 shares of the company's stock worth $109,000 after purchasing an additional 21,800 shares during the last quarter. Finally, Citadel Advisors LLC bought a new position in IO Biotech in the fourth quarter worth approximately $249,000. Hedge funds and other institutional investors own 54.76% of the company's stock.
About IO Biotech
(
Get Free Report)
IO Biotech, Inc, a clinical-stage biopharmaceutical company, develops immune-modulating therapeutic cancer vaccines based on the T-win technology platform. The company's lead product candidate, IO102-IO103, which is designed to target immunosuppressive mechanisms mediated by Indoleamine 2,3-dehydrogenase (IDO), and programmed death-ligand (PD-L1) that is in phase 3 clinical trial to treat melanoma, as well as in phase 2 clinical trial to treat lung, head and neck, bladder, and melanoma cancer.
Featured Articles
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider IO Biotech, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and IO Biotech wasn't on the list.
While IO Biotech currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Nuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
